CN Stock MarketDetailed Quotes

300254 Shanxi C&Y Pharmaceutical Group

Watchlist
  • 9.26
  • -0.29-3.04%
Market Closed May 17 15:00 CST
2.24BMarket Cap48.99P/E (TTM)

About Shanxi C&Y Pharmaceutical Group Company

The company is a listed pharmaceutical group enterprise integrating R&D, production and marketing. The company's predecessor, Shanxi Qianyuan Pharmaceutical Co., Ltd., was established on March 23, 2005. Since then, it has grown from a small pharmaceutical company with only 100 employees and 2 main products. It has provided products and services across 34 provincial administrative regions across the country, and has gradually expanded its business to the international market and precision medicine. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange GEM on August 19, 2011. In September 2014, the company changed its name to Shanxi Qianyuan Pharmaceutical Group Co., Ltd. The company changed its name to Shanxi Qianyuan Pharmaceutical Co., Ltd. in June 2010 and was successfully listed on the Shenzhen Stock Exchange GEM on August 19, 2011. In September 2014, the company changed its name to Shanxi Qianyuan Pharmaceutical Group Co., Ltd. It is mainly engaged in R&D, production and sales of pharmaceuticals and health foods, medical and health services and commercial business such as medical diagnosis, gene preservation, and pregnancy environment testing. The company's pharmaceutical product categories include anti-infectives, anti-allergic drugs, respiratory drugs, urinary system drugs, nephropathy drugs, pediatric drugs, cardiovascular drugs, antidepressants, pharmaceutical raw materials and intermediates. The main varieties are: fosfomycin, tamsulosin hydrochloride sustained-release capsules, ebastine tablets, cinacarcetin hydrochloride tablets, vitamin AD drops, ambroxol hydrochloride dispersible tablets, montmorillonite powder, fluoxetine hydrochloride capsules, apixaban tablets, rivacaban tablets, glucosamine hydrochloride (glucosamine hydrochloride) APIs), etc.; The company's health food mainly includes varieties such as Baoling Gengbao oral liquid, etc., and the company's medical and health services include Medical tests, gene preservation services, etc.

Company Profile

Short Name-A仟源医药
Symbol-A300254
Company NameShanxi C&y Pharmaceutical Group Co.,Ltd
Listing DateAug 19, 2011
Issue Price13.00
Shares Offered33.80M share(s)
FoundedMar 23, 2005
Legal Representativequn zhao
General Managerqun zhao
Secretaryjunxian yu
Accounting FirmLixin Certified Public Accountants (Special General Partnership)
Securities Representativeyuanyuan xue
Legal CounselGuo Hao Law Firm (Shanghai)
Employees479
Phone0352-6116426
Office AddressNo. 1378 Hengan Street, Economic and Technological Development Zone, Datong
Zip Code037010
Registered AddressNo. 1378 Hengan Street, Economic and Technological Development Zone, Datong City, Shanxi Province
Fax0352-6116452
Emailstock@cy-pharm.com
Business License140200400002021
BusinessLicense project: Pharmaceutical production. (For projects requiring approval according to law, business activities can only be carried out after approval by relevant departments. Specific business projects are subject to documents or licenses approved by relevant departments) General projects: technical services, technology development, technical consultation, technical exchange, technology transfer, technology promotion; manufacture of basic chemical raw materials (manufacture of licensed chemicals without hazardous chemicals, etc.). (With the exception of projects subject to approval according to law, business activities are carried out independently in accordance with the law on the basis of a business license).

Company Executives

  • Name
  • Position
  • Salary
  • lequn huang
  • Chairman,directors,Member of the Innovation and Strategy Committee
  • 89.40K
  • hairong zhong
  • Vice Chairman,directors,Member of the Innovation and Strategy Committee,Member of the Remuneration and Assessment Committee,Audit Committee Members
  • 886.80K
  • junxian yu
  • directors,Board Secretary,VP
  • 774.80K
  • qun zhao
  • directors,President,Member of the Innovation and Strategy Committee,Nomination Committee Members
  • 943.80K
  • zhukun lou
  • Independent directors,Audit Committee Member,Nomination Committee Members,Member of the Remuneration and Assessment Committee
  • 60.00K
  • tao ju
  • Independent directors,Members of the Nomination Committee,Member of the Innovation and Strategy Committee
  • 60.00K
  • hao gao
  • Independent directors,Member of the Remuneration and Assessment Committee,Audit Committee Member,Member of the Innovation and Strategy Committee
  • 60.00K
  • yuanyuan xue
  • Securities affairs representative
  • --
  • haibo zhu
  • Chairman of the Supervisory Board,auditors
  • 408.30K
  • xuhong zhang
  • auditors
  • 128.30K
  • han yin
  • VP
  • --
  • kairui luo
  • VP
  • --
  • baoping gu
  • VP
  • 735.00K
  • yanjie he
  • Chief Financial Officer
  • 558.90K
  • yingmin yu
  • Chief engineer
  • 603.30K
  • hua zhang
  • Employee supervisors
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
%Chg